A detailed history of Shell Asset Management CO transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Shell Asset Management CO holds 7,339 shares of ACAD stock, worth $116,249. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,339
Previous 4,430 65.67%
Holding current value
$116,249
Previous $139,000 2.16%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$17.79 - $30.86 $51,751 - $89,771
2,909 Added 65.67%
7,339 $136,000
Q4 2023

Feb 14, 2024

SELL
$20.78 - $31.77 $28,073 - $42,921
-1,351 Reduced 23.37%
4,430 $139,000
Q3 2023

Nov 08, 2023

SELL
$20.84 - $33.47 $1,833 - $2,945
-88 Reduced 1.5%
5,781 $120,000
Q2 2023

Jul 28, 2023

SELL
$17.8 - $25.65 $569 - $820
-32 Reduced 0.54%
5,869 $141,000
Q1 2023

May 15, 2023

SELL
$16.32 - $20.92 $326 - $418
-20 Reduced 0.34%
5,901 $111,000
Q4 2022

Feb 07, 2023

SELL
$14.2 - $18.63 $16,358 - $21,461
-1,152 Reduced 16.29%
5,921 $94,000
Q3 2022

Nov 14, 2022

SELL
$14.11 - $18.27 $26,611 - $34,457
-1,886 Reduced 21.05%
7,073 $116,000
Q2 2022

Aug 09, 2022

BUY
$13.01 - $27.22 $60,275 - $126,110
4,633 Added 107.1%
8,959 $126,000
Q1 2022

May 04, 2022

SELL
$20.94 - $27.5 $13,673 - $17,957
-653 Reduced 13.12%
4,326 $105,000
Q4 2021

Feb 09, 2022

SELL
$16.79 - $27.09 $1,376 - $2,221
-82 Reduced 1.62%
4,979 $116,000
Q3 2021

Nov 04, 2021

SELL
$15.78 - $24.77 $3,156 - $4,954
-200 Reduced 3.8%
5,061 $84,000
Q1 2021

May 10, 2021

SELL
$25.02 - $54.99 $133,156 - $292,656
-5,322 Reduced 50.29%
5,261 $136,000
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $106,334 - $147,142
-2,591 Reduced 19.67%
10,583 $566,000
Q2 2020

Aug 10, 2020

SELL
$39.26 - $52.73 $5,810 - $7,804
-148 Reduced 1.11%
13,174 $639,000
Q1 2020

May 11, 2020

SELL
$31.65 - $46.87 $6,424 - $9,514
-203 Reduced 1.5%
13,322 $563,000
Q4 2019

Feb 13, 2020

SELL
$36.21 - $51.4 $10,718 - $15,214
-296 Reduced 2.14%
13,525 $579,000
Q3 2019

Nov 12, 2019

SELL
$22.22 - $44.01 $2,644 - $5,237
-119 Reduced 0.85%
13,821 $497,000
Q2 2019

Aug 12, 2019

SELL
$23.32 - $28.12 $7,439 - $8,970
-319 Reduced 2.24%
13,940 $373,000
Q4 2018

Feb 13, 2019

SELL
$14.32 - $22.92 $17,184 - $27,504
-1,200 Reduced 7.76%
14,259 $231,000
Q2 2018

Aug 10, 2018

SELL
$15.07 - $22.34 $13,156 - $19,502
-873 Reduced 5.35%
15,459 $236,000
Q4 2017

Feb 09, 2018

BUY
$26.84 - $39.14 $438,350 - $639,234
16,332 New
16,332 $492,000
Q3 2017

Oct 18, 2017

SELL
$29.49 - $38.37 $342,732 - $445,936
-11,622 Closed
0 $0
Q1 2017

Oct 20, 2017

SELL
N/A
-4,988 Reduced 30.03%
11,622 $400,000
Q4 2016

Oct 20, 2017

SELL
N/A
-17,034 Reduced 50.63%
16,610 $479,000
Q3 2016

Oct 20, 2017

BUY
N/A
33,644
33,644 $1.07 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.56B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.